Your browser doesn't support javascript.
loading
Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease.
Oh, Gia J; Waldo, Anne; Paez-Cruz, Francisco; Gipson, Patrick E; Pesenson, Anne; Selewski, David T; Kamil, Elaine S; Massengill, Susan F; Lafayette, Richard A; Modes, Meg; Adler, Sharon G; Desmond, Hailey; Eikstadt, Richard; Attalla, Samara; Modi, Zubin J; Troost, Jonathan P; Gipson, Debbie S.
Affiliation
  • Oh GJ; Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
  • Waldo A; Division of Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Paez-Cruz F; Division of Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Gipson PE; Division of Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Pesenson A; The Polyclinic, Seattle, Washington, USA.
  • Selewski DT; Division of Nephrology, Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Kamil ES; Division of Pediatric Nephrology, Department of Pediatrics, Cedars-Sinai Medical Center, David Geffen School of Medicine at the University of California, Los Angeles, California, USA.
  • Massengill SF; Division of Pediatric Nephrology, Department of Pediatrics, Levine Children's Hospital, Charlotte, North Carolina, USA.
  • Lafayette RA; Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
  • Modes M; Livonia, Michigan, USA.
  • Adler SG; Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, California, USA.
  • Desmond H; Division of Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Eikstadt R; Division of Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Attalla S; Division of Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Modi ZJ; Division of Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Troost JP; Susan B. Meister Child Health Evaluation and Research (CHEAR) Center, University of Michigan, Ann Arbor, Michigan, USA.
  • Gipson DS; Division of Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Kidney Int Rep ; 4(11): 1608-1616, 2019 Nov.
Article in En | MEDLINE | ID: mdl-31891002
INTRODUCTION: The goal of this study was to assess the occurrence of steroid-associated adverse events (SAAE) in patients with primary proteinuric kidney disease. METHODS: The Kidney Research Network Registry consists of children and adults with primary proteinuric kidney disease. SAAEs of interest were hypertension, hyperglycemia and diabetes, overweight and obesity, short stature, ophthalmologic complications, bone disorders, infections, and psychosis. Events were identified using International Classification of Diseases, Ninth Revision/Tenth Revision codes, blood pressures, growth parameters, laboratory values, and medications. Poisson generalized estimating equations tested the association between steroid onset and dose on SAAE risk. RESULTS: A total of 884 participants were included in the analysis; 534 (60%) were treated with steroids. Of these, 62% had at least one SAAE. The frequency of any SAAE after initiation of steroids was 293 per 1000 person-years. The most common SAAEs were hypertension (173.7 per 1000 person-years), diabetes (78.7 per 1000 person-years), obesity (66.8 per 1000 person-years), and infections (46.1 per 1000 person-years). After adjustment for demographics, duration of kidney disease, estimated glomerular filtration rate (eGFR), proteinuria, and other therapies, steroid exposure was associated with a 40% increase in risk of any SAAE (Relative risk [RR]: 1.4; 95% confidence interval [CI]: 1.3-1.6). A 1-mg/kg per day increase in steroid dose was associated with a 2.5-fold increase in risk of any SAAE. CONCLUSION: Most patients with primary proteinuric kidney disease treated with steroids experienced at least one SAAE. Steroid therapy increased risk of hypertension, diabetes, weight gain, short stature, fractures, and infections after adjusting for disease-related factors. This study highlights the importance of surveillance and management of SAAE and provides rationale for the development of steroid minimization protocols.
Key words

Full text: 1 Database: MEDLINE Type of study: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Language: En Journal: Kidney Int Rep Year: 2019 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Type of study: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Language: En Journal: Kidney Int Rep Year: 2019 Type: Article Affiliation country: United States